老年肝细胞癌的治疗：管理和预后的综述。
A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes.
机构信息
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chonnam National University Medical School, Gwanjgu, Republic of Korea.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chonnam National University Medical School, Gwanjgu, Republic of Korea
出版信息
In Vivo. 2019 Sep-Oct;33(5):1411-1420. doi: 10.21873/invivo.11618.
Abstract
Recent studies report a significant age-specific increase in hepatocellular carcinoma (HCC) development among persons over 75 years old. Therefore, there is an urgent need to determine the optimal treatment strategy in elderly patients with HCC. This systemic review examines the clinical characteristics, efficacy, and safety of first-line treatment modalities. The literature was searched regarding epidemiology and clinical outcomes in elderly patients (age ≥75 years) undergoing first-line treatment for HCC. Causative or comorbid conditions of HCC in elderly patients differed from those in younger patients. Radiofrequency ablation may be effective and safe in early stages. Surgical resection may also be feasible in the early stages for selected patients. Transarterial chemoembolization may be safe and effective for intermediate HCC, and sorafenib may be feasible in elderly patients with advanced HCC. Prospective randomized trials are needed to establish the treatment strategy for elderly patients with HCC.
摘要
最近的研究报告称，75 岁以上人群中肝细胞癌 (HCC) 的发展具有明显的年龄特异性增加。因此，迫切需要确定老年 HCC 患者的最佳治疗策略。本系统评价研究了一线治疗方法的临床特征、疗效和安全性。对接受 HCC 一线治疗的老年患者（年龄≥75 岁）的流行病学和临床结局相关文献进行了检索。老年患者 HCC 的病因或合并症与年轻患者不同。射频消融在早期可能是有效和安全的。手术切除在早期也可能对选定的患者可行。经动脉化疗栓塞术可能对中期 HCC 安全有效，索拉非尼可能对晚期 HCC 的老年患者可行。需要前瞻性随机试验来确定老年 HCC 患者的治疗策略。
相似文献
1
A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes.老年肝细胞癌的治疗：管理和预后的综述。
In Vivo. 2019 Sep-Oct;33(5):1411-1420. doi: 10.21873/invivo.11618.
2
Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review.老年肝细胞癌：荟萃分析与系统文献综述
World J Gastroenterol. 2015 Nov 14;21(42):12197-210. doi: 10.3748/wjg.v21.i42.12197.
3
Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection.不宜手术切除的老年肝细胞癌患者的临床特征及预后
Geriatr Gerontol Int. 2017 Feb;17(2):189-201. doi: 10.1111/ggi.12747. Epub 2016 Feb 5.
4
Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?老年患者的肝细胞癌治疗效果是否较差？
World J Gastroenterol. 2019 Jul 21;25(27):3563-3571. doi: 10.3748/wjg.v25.i27.3563.
5
Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers.肝细胞癌全身治疗的发展态势：突破、毒性及未来前沿
Am Soc Clin Oncol Educ Book. 2019 Jan;39:248-260. doi: 10.1200/EDBK_237555. Epub 2019 May 17.
6
Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.经动脉化疗栓塞术在肝细胞癌治疗中的应用：巴塞罗那临床肝癌分期系统
World J Gastroenterol. 2015 Sep 28;21(36):10327-35. doi: 10.3748/wjg.v21.i36.10327.
7
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.肝细胞癌非手术治疗的当前标准与未来展望
Digestion. 2017;96(1):1-4. doi: 10.1159/000464282. Epub 2017 Jun 13.
8
[Hepatocellular carcinoma].肝细胞癌
Ther Umsch. 2011 Apr;68(4):213-7. doi: 10.1024/0040-5930/a000153.
9
Diagnosis and treatment of hepatocellular carcinoma.肝细胞癌的诊断与治疗
Gastroenterology. 2008 May;134(6):1752-63. doi: 10.1053/j.gastro.2008.02.090.
10
Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.基于经动脉化疗栓塞治疗的晚期肝细胞癌患者多因素生存分析的治疗算法
PLoS One. 2017 Feb 7;12(2):e0170750. doi: 10.1371/journal.pone.0170750. eCollection 2017.
引用本文的文献
1
Prognostic nutritional index is a better inflammation based prognostic marker in elderly patients with hepatocellular carcinoma after surgery.预后营养指数是老年肝细胞癌患者术后一种更好的基于炎症的预后标志物。
Sci Rep. 2025 Aug 20;15(1):30510. doi: 10.1038/s41598-025-12158-5.
2
Health-related quality of life in Thai patients with hepatocellular carcinoma and its influencing factors: A cross-sectional study.泰国肝细胞癌患者的健康相关生活质量及其影响因素：一项横断面研究。
Belitung Nurs J. 2025 Aug 3;11(4):370-383. doi: 10.33546/bnj.3853. eCollection 2025.
3
Incidence trends and disparities in infection-related malignancies of the liver among US adults, 2000-2019.2000 - 2019年美国成年人肝脏感染相关恶性肿瘤的发病率趋势及差异
Gastroenterol Rep (Oxf). 2025 Jun 16;13:goaf050. doi: 10.1093/gastro/goaf050. eCollection 2025.
4
Italian Oncology at the Crossroads: Between Hospital Bed Cuts and the Need for a Transition to Integrated Community-Based Simultaneous Care.处于十字路口的意大利肿瘤学：在削减病床与向基于社区的综合同步护理过渡的需求之间
Cancers (Basel). 2025 May 29;17(11):1821. doi: 10.3390/cancers17111821.
5
RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma.雷替曲塞联合奥沙利铂（RALOX-HAIC）与乐伐替尼联合使用可提高不可切除肝细胞癌老年患者的生存率和安全性。
BMC Cancer. 2025 May 16;25(1):882. doi: 10.1186/s12885-025-14274-x.
6
Metabolic syndrome is associated with worse prognosis in elderly patients with hepatocellular carcinoma.代谢综合征与老年肝细胞癌患者的预后较差相关。
Front Oncol. 2025 Apr 11;15:1542328. doi: 10.3389/fonc.2025.1542328. eCollection 2025.
7
Management of hepatocellular carcinoma in elderly and adolescent/young adult populations.老年及青少年/青年人群肝细胞癌的管理
J Liver Cancer. 2025 Mar;25(1):52-66. doi: 10.17998/jlc.2025.02.28. Epub 2025 Mar 20.
8
Oral Microalgae-Based Biosystem to Enhance Irreversible Electroporation Immunotherapy in Hepatocellular Carcinoma.基于口服微藻的生物系统增强肝癌不可逆电穿孔免疫疗法
Adv Sci (Weinh). 2025 Apr;12(15):e2409381. doi: 10.1002/advs.202409381. Epub 2025 Jan 28.
9
Development and Validation of a Blood-Biomarker-Based Predictive Model for HBV-Associated Hepatocellular Carcinoma.基于血液生物标志物的乙型肝炎病毒相关肝细胞癌预测模型的建立与验证。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241298230. doi: 10.1177/10760296241298230.
10
Hepatocellular carcinoma outcomes and potential implications for surveillance in elderly patients.肝细胞癌的预后及其对老年患者监测的潜在影响。
Sci Rep. 2024 Jul 4;14(1):15418. doi: 10.1038/s41598-024-66253-0.
本文引用的文献
1
Liver resection for hepatocellular carcinoma in oldest old patients.老年患者的肝细胞癌肝切除术。
World J Surg Oncol. 2019 Jan 3;17(1):1. doi: 10.1186/s12957-018-1541-0.
2
Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea.韩国高龄肝细胞癌患者的特征与结局
In Vivo. 2019 Jan-Feb;33(1):145-154. doi: 10.21873/invivo.11451.
3
The Short- and Long-Term Outcomes in Elderly Patients with Hepatocellular Carcinoma after Curative Surgery: A Case-Controlled Study with Propensity Score Matching.老年肝细胞癌患者根治性手术后的短期和长期结局：一项倾向评分匹配的病例对照研究
Eur Surg Res. 2018;59(5-6):380-390. doi: 10.1159/000494733. Epub 2018 Dec 14.
4
Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study.经皮微波凝固治疗（PMCT）老年中国原发性肝细胞癌患者的临床结局：一项符合Strobe标准的观察性研究
Medicine (Baltimore). 2018 Aug;97(35):e11618. doi: 10.1097/MD.0000000000011618.
5
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
6
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
7
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.2015 年全球疾病负担研究：1990 年至 2015 年全球、区域和国家一级原发性肝癌及相关病因负担。
JAMA Oncol. 2017 Dec 1;3(12):1683-1691. doi: 10.1001/jamaoncol.2017.3055.
8
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.老年晚期肝细胞癌患者应用索拉非尼的耐受性和结局。
Dig Liver Dis. 2017 Sep;49(9):1043-1049. doi: 10.1016/j.dld.2017.06.008. Epub 2017 Jun 23.
9
Effect of Age (over 75 Years) on Postoperative Complications and Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.年龄（75岁以上）对肝细胞癌肝切除患者术后并发症及生存的影响
J Gastrointest Surg. 2017 Apr;21(4):657-665. doi: 10.1007/s11605-016-3354-1. Epub 2017 Jan 12.
10
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.索拉非尼治疗晚期肝细胞癌患者的疗效与安全性：年龄并非问题。
Eur J Gastroenterol Hepatol. 2017 Jan;29(1):48-55. doi: 10.1097/MEG.0000000000000739.
Zotero 插件